The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer
| ISSN: |
1569-8041
|
|---|---|
| Keywords: |
adjuvant treatment ; Dukes' C colon cancer ; 5-fluorouracil ; leucovorin ; levamisole
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296353215873024 |
|---|---|
| autor | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. |
| autorsonst | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. |
| book_url | http://dx.doi.org/10.1023/A:1008351312879 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM192895281 |
| issn | 1569-8041 |
| journal_name | Annals of oncology |
| materialart | 1 |
| notes | Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer. |
| package_name | Springer |
| publikationsjahr_anzeige | 2000 |
| publikationsjahr_facette | 2000 |
| publikationsjahr_intervall | 7999:2000-2004 |
| publikationsjahr_sort | 2000 |
| publisher | Springer |
| reference | 11 (2000), S. 547-552 |
| schlagwort | adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole |
| search_space | articles |
| shingle_author_1 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. |
| shingle_author_2 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. |
| shingle_author_3 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. |
| shingle_author_4 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. |
| shingle_catch_all_1 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer. 1569-8041 15698041 Springer |
| shingle_catch_all_2 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer. 1569-8041 15698041 Springer |
| shingle_catch_all_3 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer. 1569-8041 15698041 Springer |
| shingle_catch_all_4 | Bleeker, W. A. Mulder, N. H. Hermans, J. Otter, R. Plukker, J. T. The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole adjuvant treatment Dukes' C colon cancer 5-fluorouracil leucovorin levamisole Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer. 1569-8041 15698041 Springer |
| shingle_title_1 | The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer |
| shingle_title_2 | The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer |
| shingle_title_3 | The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer |
| shingle_title_4 | The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:50:43.500Z |
| titel | The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer |
| titel_suche | The addition of low-dose leucovorin to the combination of 5-fluorouracil–levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM192895281 |